Form 4: Bionano Genomics CEO Holmlin Acquires Shares and Reports Tax Withholding

CEO R. Erik Holmlin reports acquisition of shares through stock options and withholding of shares for tax obligations related to vested PSUs.

Summary

• R. Erik Holmlin, CEO of Bionano Genomics, filed a Form 4 detailing changes in beneficial ownership.
• On March 14, 2025, Holmlin acquired 17,449 shares through stock options at an exercise price of $3.47.
• The filing also reports the withholding of 198 shares of common stock by Bionano Genomics to satisfy tax obligations related to the vesting of a PSU award granted on May 12, 2021.
• Following these transactions, Holmlin directly owns 1,783 shares of common stock and indirectly owns shares through a Robert Erik Holmlin Traditional IRA.
• The stock options vest monthly over 48 months, beginning one month after the vesting commencement date, and will be fully vested on the four-year anniversary of that date.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reflects routine transactions related to executive compensation and tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The CEO's acquisition of shares through stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.

Key Dates